Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings "We have a history of net losses. We expect to continue to incur substantial and increasing net losses for the foreseeable future, and we may never achieve or maintain profitability.", "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.", "Failure or delay in commencing or completing clinical trials for our product candidates could harm our business.", and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them." Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Alexza Pharmaceuticals, Inc.

(a development stage company)

Condensed Consolidated Statements of Operations

(unaudited, in thousands except per share data)

Three Months Ended

March 31,

2008 2007

Revenue $- $-

Operating expenses:

Research and development 14,693 10,235

General and administrative 4,462 3,585

Acquired in-process research and development - -

Total operating e
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/25/2014)... 2014 At the request of the ... 60-day extension for the public comment period (Docket No. ... Model Aircraft established by Congress as part of the ... extension establishes the new deadline for comments as September ... Transportation/FAA notice published in the Federal Register on July ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... Calabasas, CA (PRWEB) July 24, 2014 ... advancing the Global Supply Chain of the biotech ... annual SCM Innovation Awards, brought to you by ... premiere global organization of supply chain management professionals ... be given to stakeholders of the Biotech industry ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... American Stock Exchange(R),(Amex(R)) today listed the common ... symbol RNN., Rexahn Pharmaceuticals is a ... discover, develop and commercialize,innovative treatments for cancer, ... unmet medical needs. Rexahn,s compounds are designed,to ...
... Judges for Nikon Small World, MELVILLE, N.Y., ... received a record number of entries for the ... by over 300,images. The oldest and most respected ... world,s best photomicrographers who create beautiful,imagery while showing ...
... Informed Medical Communications,(IMC), a leading provider of peer-to-peer ... appointment of Bert,Marchio to the position of Executive ... ), Marchio brings to IMC over 20 ... both the public and private sectors, with the ...
Cached Biology Technology:American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc. 2Nikon Instruments Receives Record Number of Entries for Nikon Small World 2Informed Medical Communications Appoints New Chief Financial Officer 2
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... species of fish, according to a new study ... tested fish anti-predator behaviour. , Three-spined sticklebacks ... when exposed to additional noise, whereas no effects ... author Dr Irene Voellmy of Bristol,s School of ... environments have increased substantially during the last few ...
(Date:7/24/2014)... A sake brewery has its own microbial terroir, meaning ... resemble those found in the product, creating the final ... the journal Applied and Environmental Microbiology . This ... census of a sake brewery. , Many sake ... author David A. Mills of the University of California, ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
... Baylor College of Medicine (BCM) and the Puget Sound Blood ... small blood vessels of the heart and brain could cause ... clots. The scientists were surprised to find that the proteins ... five hours before returning to their normal, healthy shape. ...
... are the origins of life on Earth? A new ... building blocks of life could have been created on icy ... Chemists from the University of California, Berkeley, and the University ... of creating complex dipeptides linked pairs of amino acids ...
... discovered that deleting a specific gene in mice prevents them ... finding they believe may be replicated in humans. "When ... fat," said Prof. James McManaman, Ph.D., lead author of the ... the University of Colorado School of Medicine. "It may be ...
Cached Biology News:Stressed proteins can cause blood clots for hours 2Stressed proteins can cause blood clots for hours 3New evidence that comets could have seeded life on Earth 2Researchers discover gene that causes obesity in mice 2
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
E2F2 protein...
Biology Products: